HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,687,064 | +31.8% | 70,342 | +24.4% | 0.01% | +25.0% |
Q2 2023 | $2,039,037 | +146277.4% | 56,530 | +55.0% | 0.01% | +33.3% |
Q1 2023 | $1,393 | -25.5% | 36,482 | +10.9% | 0.01% | -33.3% |
Q4 2022 | $1,871 | -99.5% | 32,883 | +228.4% | 0.01% | +350.0% |
Q3 2022 | $395,000 | -15.4% | 10,014 | -5.8% | 0.00% | 0.0% |
Q2 2022 | $467,000 | +41.1% | 10,627 | +27.9% | 0.00% | 0.0% |
Q1 2022 | $331,000 | -3.5% | 8,307 | -2.8% | 0.00% | 0.0% |
Q4 2021 | $343,000 | +1.5% | 8,549 | +2.8% | 0.00% | 0.0% |
Q3 2021 | $338,000 | +1200.0% | 8,313 | +1350.8% | 0.00% | – |
Q2 2021 | $26,000 | +18.2% | 573 | +7.5% | 0.00% | – |
Q1 2021 | $22,000 | +4.8% | 533 | +6.6% | 0.00% | – |
Q4 2020 | $21,000 | +61.5% | 500 | 0.0% | 0.00% | – |
Q3 2020 | $13,000 | -92.0% | 500 | -91.8% | 0.00% | -100.0% |
Q2 2020 | $163,000 | +24.4% | 6,088 | -16.7% | 0.00% | 0.0% |
Q1 2020 | $131,000 | +1355.6% | 7,305 | +1361.0% | 0.00% | – |
Q4 2019 | $9,000 | – | 500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |